We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,610.00
Bid: 4,630.00
Ask: 4,634.00
Change: -15.00 (-0.32%)
Spread: 4.00 (0.086%)
Open: 4,629.00
High: 4,657.00
Low: 4,585.00
Prev. Close: 4,625.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Jez Maiden to retire as Group Finance Director

7 Nov 2022 07:00

RNS Number : 4466F
Croda International PLC
07 November 2022
 

Croda International Plc

 

Jez Maiden to retire as Group Finance Director;

Louisa Burdett appointed as successor

 

7 November 2022

 

Croda International Plc ("Croda" or "the Company") announces that Jez Maiden, Group Finance Director, has advised the Board that he will be retiring from the Company during 2023 after eight years in the role. The Board has appointed Louisa Burdett, until recently Chief Financial Officer ("CFO") of Meggitt Plc ("Meggitt"), the global aerospace, defence and energy component manufacturer, to succeed Jez.

 

Jez joined Croda in January 2015, subsequently transforming the Finance, IT and Digital functions, and developing a broad, diverse pool of talent. He has modernised Croda's processes, introduced new standards of operational excellence and financial reporting, and closely supported the Chief Executive in the development and deployment of Croda's strategy. Jez led the creation of Croda's sustainability metrics, as well as its approach to capital allocation, which has underpinned shareholder value creation by enabling investment in organic growth, targeted acquisitions and strong returns. He also co-led the successful separation of the majority of Croda's Performance Technology and Industrial Chemicals businesses, accelerating the Company's transition to be a pure-play Consumer Care and Life Sciences business.

 

Louisa has over ten years of experience successfully leading finance functions for UK listed companies. This includes four years as CFO of Meggitt, before it was acquired by Parker-Hannifin in September 2022, and five years as CFO of Victrex, the speciality chemicals company. Prior to that she held CFO positions with Optos plc, Financial Times Group, GE Healthcare, and CHEP Europe. Louisa is also Non-executive Director and Audit Committee Chair of RS Group Plc, the FTSE 100 distributor of industrial and electronic products. She has a first-class degree in biochemistry from Imperial College London and trained as an accountant before moving into her first in-house role at GSK.

 

To enable a smooth transition, Louisa will join Croda and the Board on 1 January 2023. She will succeed Jez as Group Finance Director on 13 March 2023, following Croda's 2022 Full Year results at the end of February. Jez will step down from the Board at the Annual General Meeting on 26 April 2023 and retire from the Company on 31 May 2023.

 

Commenting, Anita Frew, Croda Chair said: 

"On behalf of the Board and all my Croda colleagues, I would like to thank Jez for his outstanding contribution over the last eight years. He has been instrumental in the development and growth of Croda, always nurturing a culture of transformation. I have hugely appreciated his diligence, intellect and thoughtful approach, particularly his contribution to Board debate, and wish him the very best wishes for the future.

 

"I am delighted that we have been able to appoint Louisa as Group Finance Director. She has an exceptional ten-year track record as a CFO of listed companies, with valuable experience both in speciality chemicals and the broader manufacturing sector. We look forward to welcoming Louisa to Croda in the New Year."

 

There are no further details required to be disclosed under LR 9.6.13R of the Listing Rules of the UK Listing Authority.

-ENDS-

 

For enquiries contact:

Investors:

David Bishop, Croda

+44 7823 874428

Reece De Gruchy, Croda

+44 7826 548908

Press:

Charlie Armitstead, Teneo

+44 7703 330269

 

About Croda - www.croda.com

Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world's most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.

Croda is a FTSE 100 company with over 5,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™. As part of this Purpose, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZLFBLFLBFBD
Date   Source Headline
25th Apr 202410:01 amRNSResult of AGM
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.